Randomized phase II study of biweekly cetuximab versus panitumumab in patients not combination of irinotecan wild-type KRAS metastatic colorectal cancer following treatment with fluoropyrimidine and oxaliplatin chemotherapy
Phase 2
- Conditions
- advanced colorectal cancer
- Registration Number
- JPRN-UMIN000006899
- Lead Sponsor
- Tsukuba Center Clinical Trial Group(TCTG)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 90
Inclusion Criteria
Not provided
Exclusion Criteria
1)having other active malignancies 2) severe complications (uncontrolled diabetes mellitus, interstitial lung disease, pulmonary fibrosis, heart failure ,renal failure, hepatic failure, etc.) 3) having active infections 4) history of severe drug hypersensitivity 5) uncontrollable serious mental problem 7) pregnant or female intend to be pregnant, and male intend to make pregnant. 8) Others
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method overall survival
- Secondary Outcome Measures
Name Time Method response rate,time to treatment failureprogression free survival,safety